
|Articles|April 4, 2022
Daily Medication Pearl: Tolterodine Tartrate (Detrol LA)
Author(s)Saro Arakelians, PharmD
Tolterodine Tartrate (Detrol LA) is an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Advertisement
Medication Pearl of the Day: Tolterodine Tartrate (Detrol LA)
Indication: Tolterodine Tartrate (Detrol LA) is an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Insight:
- Dosing: 4 mg capsules taken orally once daily with water and swallowed whole; 2 mg capsules taken orally once daily with water and swallowed whole in the presence of mild to moderate hepatic impairment (Child-Pugh class A or B), severe renal impairment [Creatinine Clearance (CCr) 10–30 mL/min], and drugs that are potent CYP3A4 inhibitors.
- Adverse events: The most common adverse reactions (incidence ≥4% and >placebo) were dry mouth, headache, constipation, and abdominal pain.
- Mechanism of action: Tolterodine acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors.
- Manufacturer: Pfizer
Reference
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
2
A First-of-Its-Kind All-Oral Option Receives FDA Approval for Newly Diagnosed AML
3
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
4
Sonrotoclax Approval Delivers a Long-Awaited New Option for Relapsed or Refractory Mantle Cell Lymphoma
5

































































































































